Merck, Ablynx ink immunotherapy deal

Share this article:

Merck and Belgium's Ablynx have signed their second collaboration and licensing deal. Ablynx announced the $27-million partnership Monday. The agreement focuses on nanobodies that can be deployed for immuno-oncology treatments. The three-year research agreement also promises up to $14.5 million in research funding and royalties that could reach $2.3 billion.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.